Related Experiment Video

Updated: Jul 10, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Acid ceramidase inhibition: a novel target for cancer therapy

Xiang Liu1, Saeed Elojeimy, Lorianne S Turner

  • 1Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed

Insights

Restoring sphingolipid balance by inhibiting acid ceramidase increases ceramide and decreases sphingosine-1-phosphate. This approach sensitizes cancer cells to radiation and gene therapy, enhancing treatment efficacy.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Sphingolipid deregulation, particularly the ceramide/sphingosine-1-phosphate balance, is crucial in cancer pathology and therapeutic resistance.
  • Over-expression of acid ceramidase in cancer cells contributes to treatment resistance.

Purpose of the Study:

  • To develop drugs that restore normal sphingolipid balance by increasing ceramide and decreasing sphingosine-1-phosphate.
  • To investigate the potential of acid ceramidase inhibitors as sensitizers in cancer therapy.

Main Methods:

  • Targeting the ceramide metabolizing enzyme, acid ceramidase.
  • Utilizing acid ceramidase inhibitors in combination with radiation or gene therapy.

Main Results:

  • Inhibition of acid ceramidase effectively modulates sphingolipid metabolism.
  • Acid ceramidase inhibitors act as sensitizers, enhancing the efficacy of radiation and gene therapy.

Conclusions:

  • Targeting acid ceramidase is a promising strategy for restoring sphingolipid balance in cancer.
  • Combination therapy involving acid ceramidase inhibitors offers a novel approach to overcome cancer resistance and improve treatment outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...